Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Prestige Consumer Healthcare (PBH)

Prestige Consumer Healthcare Q1 revenue falls 4.4% to $267.1 million; outlook reaffirmed

Negative Impact 3 of 5 earnings Written later

Prestige Consumer Healthcare reported fiscal first quarter 2025 results for the quarter ended June 30, 2024. Revenue fell 4.4% to $267.1 million and diluted EPS was $0.98, versus $1.06 a year earlier, while the company said results were ahead of its own expectations. The company reaffirmed its full-year fiscal 2025 outlook, so shareholders face lower year-over-year earnings with guidance unchanged.

Key points

  • Revenue of $267.1 million, down 4.4% from $279.3 million; organic revenue down 4.3%
  • Diluted EPS of $0.98 vs. $1.06 a year earlier; adjusted diluted EPS of $0.90
  • Operating cash flow of $54.8 million vs. $48.1 million; about 0.4 million shares repurchased for $26.0 million
  • Fiscal 2025 outlook reaffirmed: revenue of $1,125 million to $1,140 million; adjusted diluted EPS of $4.40 to $4.46

The filing

CompanyPrestige Consumer Healthcare (PBH)
Form8-K, current report
Filed with the SECAug 8, 2024, 6:03 AM ET
Accession number0001295947-24-000023

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 08, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.